The Native Antigen Company introduces custom contract service for influenza researchers
The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.
- For more information, visit: thenativeantigencompany.com/influenza-services-landing-page
Supplier: [No title]
Website: https://thenativeantigencompany.com/influenza-services-landing-page
